Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • 15 years after a giant leap for cancer genomics
    Editorial

    Cai, S. F.; Levine, R. L.
    Nature (2023)

    Fulltext@MSK | Save
  • Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemia: Topline efficacy and safety results from the pivotal Augment-101 phase 2 study
    Meeting Abstract

    Aldoss, I.; Issa, G. C.; Thirman, M.; DiPersio, J.; Arellano, M.; Blachly, J. S.; Mannis, G. N.; Perl, A.; Dickens, D. S.; McMahon, C. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Role of ERK1/2 kinases in megakaryopoiesis, thrombopoiesis, platelet function and thrombosis in myeloproliferative neoplasms
    Meeting Abstract

    Albrecht, C.; Stivala, S.; Vokalova, L.; Knopp, T.; Angelillo-Scherrer, A.; Levine, R.; Neel, B.; Meyer, S.
    Swiss Medical Weekly (2023)

    Fulltext@MSK | Save
  • Growth differentiation factor 15, a potential biomarker and a therapeutic target in myeloproliferative neoplasms
    Meeting Abstract

    Uda, N. R.; Stüdle, C.; Müggler, A.; Ueltschi, O.; Brunner, M.; Silzle, T.; Joachim, W.; Leković, D.; Lee, S. J.; Vannucchi, A. M.; more...
    Swiss Medical Weekly (2023)

    Fulltext@MSK | Save
  • Assessing the burden of adverse events in a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Stilgenbauer, S.; Seymour, J. F.; Byrd, J. C.; Munir, T.; Ghia, P.; Kater, A. P.; Chanan-Khan, A.; Furman, R. R.; O'Brien, S. M.; Brown, J. R.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Comparing acalabrutinib and ibrutinib in the real world: A study of 2,509 patients with chronic lymphocytic leukemia
    Meeting Abstract

    Christofyllakis, K.; Roeker, L.; DerSarkissian, M.; Ryan, K. J.; Chen, Y.; Wahlstrom, S. K.; Hakre, S.; Yu, L.; Guo, H.; Mato, A. R.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Neopeptide diversity and similarity to the unmutated immunopeptidome is associated with response to immune checkpoint blockade therapy
    Meeting Abstract

    Klatt, M.; Molvi, Z.; Panageas, K.; Wells, D.; Hellmann, M.; Merghoub, T.; Wolchok, J.; O'Reilly, R.; Keller, U.; Scheinberg, D.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Preliminary data from the phase I/II study of TP-3654, an oral PIM-1 kinase inhibitor, in patients with myelofibrosis
    Meeting Abstract

    El Chaer, F.; Yuda, J.; Mccloskey, J.; Rein, L.; Brown, R.; Green, S.; Pu, J.; Shirane, S.; Shimoda, K.; Ichii, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Host interactions with engineered T-cell micropharmacies
    Journal Article

    Bourne, C. M.; Wallisch, P.; Dacek, M. M.; Gardner, T. J.; Pierre, S.; Vogt, K.; Corless, B. C.; Bah, M. A.; Romero-Pichardo, J. E.; Charles, A.; more...
    Cancer Immunology Research (2023)

    Fulltext@MSK | Save
  • Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression
    Journal Article

    Stein, E. M.; de Botton, S.; Cluzeau, T.; Pigneux, A.; Liesveld, J. L.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Braun, T.; Roboz, G. J.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save